Sugi Predict

Sugi Predict / Compounds / SCHEMBL2537519

SCHEMBL2537519

SCHEMBL2537519

CN1CCC(C(=O)N(C)C)CC1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 1/20 0.42
▸ CYP2D6 P10635 1/20 0.39
▸ DPP4 P27487 1/20 0.39
▸ CYP46A1 Q9Y6A2 6/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ HTT P42858 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21633062 0.92 BCHE (0.39) BCHECYP2D6DPP4CYP46A1ALDH1A1
SCHEMBL10202190 0.92 BCHE (0.49) BCHECYP2D6DPP4CYP46A1ALDH1A1
SCHEMBL12225732 0.87 BCHE (0.47) BCHECYP2D6DPP4ALDH1A1MEN1
SCHEMBL2743218 0.87 BCHE (0.47) BCHECYP2D6DPP4ALDH1A1MEN1
SCHEMBL14155735 0.87 BCHE (0.47) BCHECYP2D6DPP4ALDH1A1MEN1
SCHEMBL13817646 0.81 CCR5 (0.46) DPP4CYP46A1ALDH1A1KMT2ALMNA
SCHEMBL11947855 0.81 BCHE (0.37) BCHECYP2D6DPP4HTT
SCHEMBL11209804 0.80 CYP2D6 (0.38) BCHECYP2D6DPP4CYP46A1MEN1
SCHEMBL3902887 0.80 CYP2D6 (0.38) BCHECYP2D6DPP4CYP46A1MEN1
SCHEMBL197080 0.80 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081363-A1 COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER Revolution Medicines, Inc. (US) 2024-04-18 — — WO disclosed
WO-2023172940-A1 METHODS FOR TREATING IMMUNE REFRACTORY LUNG CANCER Revolution Medicines, Inc. (US) 2023-09-14 — — WO disclosed
EP-3262036-B1 THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2023-09-13 — — EP disclosed
EP-3596061-B1 COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER ARGONAUT THERAPEUTICS LTD (GB) 2023-09-06 — — EP disclosed
WO-2023107722-A1 COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS PROTHENA BIOSCIENCES LIMITED (IE) 2023-06-15 — — WO disclosed
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2023-06-01 — — US disclosed
EP-3994131-B1 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN MOEHS IBERICA SL (ES) 2023-05-24 — — EP disclosed
US-20230098051-A1 PROCESS FOR THE PREPARATION OF LASMIDITAN AND OF A SYNTHESIS INTERMEDIATE OLON S.P.A. (IT) 2023-03-30 — — US disclosed
CN-110981854-B Synthesis method of 2-amino-6- (1-alkyl piperidine-4-carbonyl) pyridine compound 南京三元阳普医药科技有限公司 2023-03-28 — — CN disclosed
CN-111943930-B Synthesis process of Lasmidinan 南京三元阳普医药科技有限公司 2022-11-01 — — CN disclosed
US-20080081809-A1 Novel Compounds KUDOS PHARMACEUTICALS LIMITED (GB) 2008-04-03 — — US disclosed
WO-2008022979-A1 NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-02-28 — — WO disclosed
US-7244752-B2 N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-17 — — US disclosed
US-7244752-B2 N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-17 — — US disclosed
US-20070135447-A1 N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication SURLERAUX DOMINIQUE LOUIS N G 2007-06-14 — — US disclosed
US-20070135447-A1 N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication SURLERAUX DOMINIQUE LOUIS N G 2007-06-14 — — US disclosed
EP-1492786-B1 PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS LILLY CO ELI (US) 2006-10-04 — — EP disclosed
US-20050222206-A1 Pyridinoylpiperidines as 5-ht1f agonists ELI LILLY AND COMPANY 2005-10-06 — — US disclosed
EP-1492786-A1 PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 2005-01-05 — — EP disclosed
WO-2003084949-A1 PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS ELI LILLY AND COMPANY (US) 2003-10-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230098051-A1 PROCESS FOR THE PREPARATION OF LASMIDITAN AND OF A SYNTHESIS INTERMEDIATE LPXN, AGT, REN BCHE 1248/4885CYP2D6 422/4885DPP4 1617/4885
US-20080081809-A1 Novel Compounds SLC10A1, ABCB11, PKD1 BCHE 4519/4885CYP2D6 728/4885DPP4 4010/4885
US-20050222206-A1 Pyridinoylpiperidines as 5-ht1f agonists HTR1F, HTR1A, HTR1E BCHE 2748/4885CYP2D6 1097/4885DPP4 2411/4885
US-20070135447-A1 N-(on SO2 ) (2-hydroxy-3-substituted aminopropyl)-substituted; inhibiting retroviral replication NR0B1, NR0B2, NR2C2 BCHE 4183/4885CYP2D6 188/4885DPP4 4842/4885
US-20230167131-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI2, PADI6 BCHE 1092/4885CYP2D6 460/4885DPP4 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.